Antidote is a digital health company on a mission. Our aim is to accelerate breakthroughs in potentially life-saving treatments by bridging the gap between medical research and the people who need it. “In a world where 80% of clinical trials are delayed or closed due to lack of awareness, we use cutting-edge technology to match the right patients with the right trials. We’re helping medical researchers make progress, faster – and offering new treatment options to patients in need.”
Aegle Therapeutics Corp. is a first in class, Phase 1/2a ready, biotechnology company isolating extracellular vesicles (“EVs”) from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa (“EB”), a rare pediatric connective tissue disorder, and to prevent scarring. Aegle’s EV therapy, using its proprietary platform isolation technology, has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells. Aegle believes its therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction and improve overall cosmesis.
We are excited to announce that Rich Bendis of BioHealth Innovation will be the keynote speaker at the 2019 Technology Showcase. Now in its third year, the Technology Showcase promises to be a “must attend” event for biotech stakeholders in Maryland/DC/VA region. Check out the event page to learn more about our keynote speaker and some of the great panel sessions that we have planned.
Make sure to reserve time on your calendar for the afternoon of Wednesday, June 12.
The 2019 Technology Showcase is a half-day event that will showcase technologies being developed at the NCI and the Frederick National Laboratory for Cancer Research (FNLCR) to encourage startup company formation, technology licensing and collaborations. Innovators, entrepreneurs, investors and business development professionals should attend.
University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850
Register NOW: https://tinyurl.com/BHISBIR2019
- 8:00 a.m. – Networking and Registration
- 8:30 a.m. – Welcome
- 8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
- 9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
- 10:00 a.m. – BREAK
- 10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
- 11:00 a.m. – BREAK
- 11:15 a.m. – SBIR Funding Opportunities with USAMRC
- 11:45 a.m. – Lunch
- 12:45 p.m. – (1:1 Room Set)
- 1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
- 1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
- 2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
- 2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
- 3:00 p.m. – 1:1 Meetings* (NIH only)
- 4:00 p.m. – Adjourn
Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019
No charge for entrepreneurs to attend • NOTE: Most 1:1 meeting(s) timeslots now are booked but when you list your agency interests in the RSVP we will be certain to let them know to follow up with you with more information.
This new program is specifically aimed at helping patients with Type 2 diabetes, who take medications to control their blood sugar levels.
Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? business/commercialization plan, pitch deck, or idea?
Schedule your feedback session with BHI EIRs on one of the following dates:
- 2/27
- 3/20
- 5/22
(30 minute blocks of time beginning at 9:00 in the morning. If the morning slots are filled, more time will be allotted beginning at 1 p.m.)
Pre-registration is required; sign up here (“EIR resource”at BHI). For questions/more information, contact BHI.
- How do you obtain coverage and payment for your technology?
- Is the process different for medical devices from diagnostics or therapeutics?
- Can digital apps be reimbursed?
- How do I work with bundled payments?
- What is the process for securing reimbursement codes? Do I need different strategies based upon the point of care?
- How much do I need to budget for a reimbursement strategy? When do I need one?
- How to I talk to investors about my reimbursement strategy?
Learn the answers to these questions and more through the November 14th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 11/13 is required).
- 8:15 a.m. Networking and Coffee
- 8:30 a.m. – Issues Overview (in person/by videoconference)
- Speakers: Brian Abraham, Founder, Lara Reimbursement Advisory
- Luis Gutierrez, Entrepreneur-in-Residence, NHLBI and BioHealth Innovation
- 9:30 a.m. – 1:1 Office Hours (in person/by videoconference)*
This program is cosponsored by BioHealth Innovation, Launch Workplaces, TEDCO and Montgomery County. It is open to anyone in the BioHealth Capital Region.
To register/For more information, email: BHI@BioHealthInnovation. (In person 1:1 scheduling: www.tinyurl.com/BHIappointments.)
*Attendance at Overview in person/by videoconference required to participate in 1:1 sessions.
TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announced today the formation of TaiRx US, a new joint venture. The mission of the new company is to develop therapeutics and precision medicine diagnostics focused on the Nodal protein, a critical mediator of aggressive cancer progression and treatment resistance.
TaiRx, Inc and BHI have formed TaiRx US, which will be based in Rockville (Montgomery County), Maryland, to develop and commercialize a unique monoclonal antibody with the potential to reverse drug resistance in various tumor types. The company is also working to develop a companion diagnostic to accurately identify those patients who can best benefit from the therapy.